Medical Dosimetry
Volume 34, Issue 4 , Pages 279-284 , Winter 2009

Obtaining Normal Tissue Constraints Using Intensity Modulated Radiotherapy (IMRT) in Patients with Oral Cavity, Oropharnygeal, and Laryngeal Carcinoma

Received 16 October 2008 ,Accepted 25 November 2008.

References 

  1. Braaksma MM, Wijers OB, van Sornsen de Koste JR, et al. Optimisation of conformal radiation therapy by intensity modulation: Cancer of the larynx and salivary gland function. Radiother. Oncol. 2003;66:291–302
  2. Chao KS, Low DA, Perez CA, et al. Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience. Int. J. Cancer. 2000;90:92–103
  3. Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001;50:695–704
  4. Chao KS. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Semin. Radiat. Oncol. 2002;12(Suppl 1):20–25
  5. Eisbruch A, Ten Haken RK, Kim HM, et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 1999;45:577–587
  6. Parliament MB, Scrimger RA, Anderson SG, et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity-modulated radiotherapy (IMRT) for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004;58:663–673
  7. Roesink JM, Schipper W, Busschers W, et al. A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: Implications for future trials. Int. J. Radiat. Oncol. Biol. Phys. 2005;63:1006–1009
  8. Munter MW, Hoffner S, Hof H, et al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: Comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int. J. Radiat. Oncol. Biol. Phys. 2007;67:651–659
  9. Hunt MA, Jackson A, Narayana A, et al. Geometric factors influencing dosimetric sparing of the parotid glands using IMRT. Int. J. Radiat. Oncol. Biol. Phys. 2006;66:296–304
  10. Pedersen AM, Bardow A, Jensen SB, et al. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis. 2002;8:117–129
  11. Cooper JS, Fu K, Marks J. Late effects of radiation therapy in the head and neck region. Int. J. Radiat. Oncol. Biol. Phys. 1995;31:1141–1164
  12. Bussels B, Maes A, Flamen P, et al. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother. Oncol. 2004;73:297–306
  13. Harrison LB, Zelefsky MJ, Pfister DG, et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck. 1997;19:169–175
  14. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2004;97:28–46
  15. Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N. Engl J. Med. 1993;329:390–395
  16. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 2000;18:3339–3345
  17. Antonadou D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002;52:739–747
  18. Sasse AD, Clark LG, Sasse EC, et al. Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 2006;64:784–791
  19. Buentzel J, Micke O, Adamietz A, et al. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled phase III study. Int. J. Radiat. Oncol. Biol. Phys. 2006;64:684–691
  20. Blanco AI, Chao KS, El Naqa I, et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2005;62:1055–1069
  21. Amosson CM, Teh BS, Van TJ, et al. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. Int. J. Radiat. Oncol. Biol. Phys. 2003;56:136–144
  22. Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: A follow-up study 7 to 11 years after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1994;28:847–856
  23. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 2006;66:981–991
  24. Astreinidou E, Dehnad H, Terhaard CH, et al. Level II lymph nodes and radiation-induced xerostomia. Int. J. Radiat. Oncol. Biol. Phys. 2004;58:124–131
  25. Shah JP, Medina JE, Shaha AR, et al. Cervical lymph node metastasis. Curr. Probl. Surg. 1993;30:1–335
  26. Gregoire V, Coche E, Cosnard G, et al. Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy (Proposal for standardizing terminology and procedure based on the surgical experience). Radiother. Oncol. 2000;56:135–150
  27. Chao KSC. Practical Essentials of Intensity Modulated Radiation Therapy. 2nd ed.. Philadelphia: Lippincott Williams and Wilkins; 2005;
  28. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int. J. Radiat. Oncol. Biol. Phys. 2002;53:12–22
  29. Chao KS, Ozyigit G, Tran BN, et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003;55:312–321
  30. Robar JL, Day A, Clancey J, et al. Spatial and dosimetric variability of organs at risk in head-and-neck intensity modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2007;68:1121–1130
  31. Manning MA, Wu Q, Cardinale RM, et al. The effect of setup uncertainty on normal tissue sparing with IMRT for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001;51:1400–1409
  32. Siebers JV, Keall PJ, Wu Q, et al. Effect of patient setup errors on simultaneously integrated boost head and neck IMRT treatment plans. Int. J. Radiat. Oncol. Biol. Phys. 2005;63:422–433

PII: S0958-3947(08)00169-6

doi: 10.1016/j.meddos.2008.11.001

Medical Dosimetry
Volume 34, Issue 4 , Pages 279-284 , Winter 2009

Article Tools

* Image Usage & Resolution